SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. -- ALXN

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc. ("Alexion Pharmaceuticals" or the "Company") ALXN concerning possible violations of federal securities laws.

On June 6, 2016, Alexion announced that Soliris, the Company's treatment for myasthenia gravis, failed to meet its primary goal in a final-stage trial. In a Phase 3 clinical study, patients taking the drug did not report statistically significant changes in the daily activities they could perform after 26 weeks of treatment when compared to those on a placebo. Following this news, shares of Alexion Pharmaceuticals were down more than 10% on intraday trading on June 7, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/alexion-alxn

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160607006495/en/